Sugi Predict

Sugi Predict / Compounds / SCHEMBL2789396

SCHEMBL2789396

SCHEMBL2789396

Cc1c(-c2cccc(F)c2)cc(C(C)(C)C)c(O)c1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLRA3 O75311 1/20 0.49
▸ GLRB P48167 1/20 0.49
▸ CSNK1D P48730 2/20 0.39
▸ GSK3A P49840 2/20 0.39
▸ GSK3B P49841 2/20 0.39
▸ DYRK1A Q13627 2/20 0.39
▸ AURKB Q96GD4 2/20 0.39
▸ PLK4 O00444 1/20 0.39
▸ AURKA O14965 1/20 0.39
▸ DAPK3 O43293 1/20 0.39
▸ CHEK2 O96017 1/20 0.39
▸ CDK1 P06493 1/20 0.39
▸ PIM1 P11309 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ FLT4 P35916 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ MAPK9 P45984 1/20 0.39
▸ PLK1 P53350 1/20 0.39
▸ CSNK2A1 P68400 1/20 0.39
▸ PLK3 Q9H4B4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2789439 0.87 GLRA3 (0.54) GLRA3GLRBDHODH
SCHEMBL2789477 0.86 GLRA3 (0.57) GLRA3GLRBPTPN5
SCHEMBL2787696 0.85 GLRA3 (0.53) GLRA3GLRBGPR35DHODH
SCHEMBL2790732 0.85 GLRA3 (0.47) GLRA3GLRBTOP2ADHODHPTPN5
SCHEMBL2789496 0.83 GLRA3 (0.50) GLRA3GLRBDHODHCD274KMO
SCHEMBL4121457 0.82 GLRA3 (0.47) GLRA3GLRBNR4A2PTPN5
SCHEMBL2790750 0.82 GLRA3 (0.47) GLRA3GLRBGPR35
SCHEMBL2789240 0.82 GLRA3 (0.49) GLRA3GLRBDHODH
SCHEMBL4116240 0.81 GLRA3 (0.46) GLRA3GLRB
SCHEMBL4122027 0.80 GLRA3 (0.69) GLRA3GLRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 — — US claimed
EP-1881961-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2008-01-30 — — EP claimed
WO-2006120178-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2006-11-16 — — WO claimed
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 — — US disclosed
EP-1881961-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2008-01-30 — — EP disclosed
WO-2006120178-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2006-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES RPS12, GPR119, ATP12A GLRA3 1540/4885GLRB 1915/4885CSNK1D 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.